MRI of the sacral plexus and sacral nerve roots in children with neurogenous bladder dysfunction with sacral or spinal anomalies

Completed

Conditions: bladder dysfunction
spinal dysraphism
10029299
10041543
10004994

Registration Number: NL-OMON37843

Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 10

Inclusion Criteria

age > 8 years
diagnosed with spinal dysraphism or sacral anomalies and neurogenous bladder which are already scheduled to have a MRI scan for diagnostic reasons.
Parents/guardian and child >12 years need to be able and willing to sign informed consent

Exclusion Criteria

contra indication of MRI (i.e. claustrofobia, pacemaker)
Parents/guardian and child don't want to be informed of accidental findings
Children of employees of the divisions Paediatric Urology and Radiology of the UMC Utrecht

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study parameter is the anatomy and organisation of the sacral<br /><br>plexus in the patient population in comparison to the organisation in healthy<br /><br>individuals (from study 10/418). In order to be able to answer this question,<br /><br>the anatomy and organisation of the sacral plexus in the patient group will be<br /><br>compared qualitatively with the gained anatomical knowledge of the sacral<br /><br>plexus from the previous healthy subject study. The hypothesis is that in<br /><br>children with Spina Bifida a disrupted organisation of the nerves will be<br /><br>revealed. In children with sacral agenesis a disrupted course of the nerves is<br /><br>expected, because the sacrum has a disrupted development.<br /><br><br /><br>In order to further validate and quantify findings regarding anatomy and<br /><br>organization of the sacral plexus, two secondary parameters will also be used,<br /><br>these are described below.</p><br>

Secondary Outcome Measures